Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Apple Restores Telegram to App Store After Content Policy Violation 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
EDISON, N.J., April 03, 2018 -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced today that three abstracts have been accepted for poster presentations by the Scientific Program Committee of The International Liver Congress™ 2018 to be held in Paris, France from April 11-15, 2018.
Robert Foster, Pharm D., Ph.D, Chief Scientific Officer of ContraVir Pharmaceuticals, will present all three posters and will be available for interviews onsite at the ILC Press Office.
Abstract #1: Pharmacokinetic-Pharmacodynamic Modeling of Tenofovir Exalidex in HBV Subjects
- Abstract Number: 3094
- Date and Time: April 13, 2018 from 9:00 AM to 5:00 PM
- Session: Viral Hepatitis B/D: Therapy
Abstract #2: Assessing the in vitro anti-HBV Activity of Combinations including CRV431, TXL, and Prototype Capsid Assembly Modulators
- Abstract Number: 2615
- Date and Time: April 14, 2018 from 9:00 AM to 5:00 PM
- Session: Viral Hepatitis A, B, C, D, E: Virology
Abstract #3: HBV Peptide Array Demonstrates Candidate Mechanisms of CRV431 Anti-HBV Activity
- Abstract Number: 2624
- Date and Time: April 14, 2018 from 9:00 AM to 5:00 PM
- Session: Viral Hepatitis A, B, C, D, E: Virology
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The company is developing two novel anti-HBV compounds with complementary mechanisms of action. TXL™, designed to deliver high intrahepatic concentrations of TFV while minimizing off-target effects caused by high levels of circulating TFV (bone and kidney), recently completed a Phase 2a trial. CRV431, the other anti-HBV compound, is a next-generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. In vitro and in vivo studies have thus far demonstrated that CRV431 reduces HBV DNA and other viral proteins, including surface antigen (HBsAg). For more information visit www.contravir.com
For further information, please contact:
Sharen Pyatetskaya
Director of Investor Relations
[email protected]; (732) 902-4028
